GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 10,501 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,501 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $76.75, for a total transaction of $805,951.75. Following the transaction, the chief executive officer now directly owns 71,146 shares of the company’s stock, valued at $5,460,455.50. The trade was a 12.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Katherine Stueland also recently made the following trade(s):

• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total value of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total value of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $143,456.40.

GeneDx Stock Down 2.9 %

Shares of WGS traded down $2.27 during midday trading on Wednesday, reaching $76.93. The stock had a trading volume of 1,156,038 shares, compared to its average volume of 458,372. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company’s fifty day simple moving average is $71.26 and its two-hundred day simple moving average is $46.55. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -24.74 and a beta of 2.03. GeneDx Holdings Corp. has a 1-year low of $1.76 and a 1-year high of $89.11.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. The company had revenue of $76.90 million for the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. GeneDx’s quarterly revenue was up 44.3% on a year-over-year basis. During the same period last year, the firm earned ($0.82) earnings per share. Equities research analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC acquired a new stake in GeneDx during the second quarter worth approximately $34,000. nVerses Capital LLC purchased a new position in shares of GeneDx in the 2nd quarter valued at $50,000. CWM LLC acquired a new stake in GeneDx during the 3rd quarter worth $89,000. SG Americas Securities LLC purchased a new stake in GeneDx in the third quarter valued at $198,000. Finally, Point72 DIFC Ltd acquired a new position in GeneDx in the third quarter valued at $220,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on the stock. The Goldman Sachs Group raised their price target on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wells Fargo & Company lifted their target price on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Finally, Craig Hallum upped their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, GeneDx has a consensus rating of “Moderate Buy” and an average price target of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.